Lysosomal impairment in Parkinson's disease.
Bordeaux, France. In Mov Disord, Jun 2013
Conversely, mutations in lysosomal-related genes, such as glucocerebrosidase (GBA) and lysosomal type 5 P-type ATPase (ATP13A2), have been linked to PD.
Monogenic Parkinson's disease and parkinsonism: clinical phenotypes and frequencies of known mutations.
Lund, Sweden. In Parkinsonism Relat Disord, Apr 2013
Changes in a long list of additional genes have been suggested as causes for parkinsonism or PD, including genes for hereditary ataxias (ATXN2, ATXN3, FMR1), frontotemporal dementia (C9ORF72, GRN, MAPT, TARDBP), DYT5 (GCH1, TH, SPR), and others (ATP13A2, CSF1R, DNAJC6, FBXO, GIGYF2, HTRA2, PLA2G6, POLG, SPG11, UCHL1).
The genetics of Parkinson's disease: progress and therapeutic implications.
Bethesda, United States. In Mov Disord, 2013
Notably, whereas most mutations, such as those in SNCA, PINK1, PARK2, PARK7, PLA2G6, FBXO7, and ATP13A2, are a rare cause of disease, one particular mutation in LRRK2 has been found to be common in certain populations.
Manganese and the brain.
London, United Kingdom. In Int Rev Neurobiol, 2012
While a number of proteins such as the divalent metal transporter 1, the transferrin/transferrin receptor complex, the ZIP family metal transporters ZIP-8 and ZIP-14, the secretory pathway calcium ATPases SPCA1 and SPCA2, ATP13A2, and ferroportin have been suggested to play a role in Mn transport, the degree that each of them contributes to Mn homeostasis has still to be determined.
Parkinson's disease: from genetics to treatments.
Taipei, Taiwan. In Cell Transplant, 2012
The molecular investigations of proteins encoded by PD-linked genes have clarified that ADPD is associated with α-synuclein and LRRK2, while ARPD is linked to Parkin, PINK1, DJ1, and ATP13A2.
ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodies.
Sydney, Australia. In Acta Neuropathol Commun, 2012
BACKGROUND: ATP13A2 (PARK9) loss of function mutations are a genetic cause of an early-onset form of Parkinson's disease (PD), with in vitro studies showing that ATP13A2 deficits lead to lysosomal and mitochondrial dysfunction and α-synuclein accumulation, while elevated ATP13A2 expression reduces α-synuclein toxicity.